Maltese
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Monotard (insulin human) - A10AC01

Updated on site: 08-Oct-2017

Isem tal-MediċinaMonotard
Kodiċi ATCA10AC01
Sustanzainsulin human
ManifatturNovo Nordisk A/S

MONOTARD

EPAR summary for the public

This document is a summary of the European Public Assessment Report (EPAR). It explains how the Committee for Medicinal products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.

What is Monotard?

Monotard is an insulin suspension for injection. Monotard is supplied as 40 or 100 IU strengths in vials. Monotard contains the active ingredient insulin human (rDNA).

Monotard is used in patients with diabetes mellitus. Monotard can be used in type 1 diabetes, when the pancreas cannot produce insulin, and in type 2 diabetes, when the body is not able to use insulin

effectively.

Product

The medicine can only be obtained with a prescription.

How is Monotard used?

Monotard is given subcutaneously (under the skin) by injection, usually in the thigh. If convenient it may also be given in the abdominal wall (tummy), the buttocks or the deltoid region (shoulder). The patient's blood sugar should be tested regularly to find the lowest effective dose. In type 1 diabetes, the dosage varies between 0.5 and 1.0 IU/kg (0.7 and 1.0 IU/kg in children before puberty), in type 2 diabetes the dosage is 0.3 to 0.6 IU/kg. Monotard is a long-acting insulin, it can be given as a once daily or twice daily injection, with or without a fast-acting insulin (at meal times), according to the doctor’s recommendation.

Kummenti

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
  • Għajnuna
  • Get it on Google Play
  • Dwar
  • Info on site by:

  • Presented by RXed.eu

  • 27558

    Drogi ta’ preskrizzjoni elenkati